Josh Bilenker is the interim senior vice president of oncology research and early phase development at Eli Lilly and Company. Dr. Bilenker was the founding CEO of Loxo Oncology, Inc., which was acquired by Lilly in 2019. From 2006 to 2013, Dr. Bilenker worked as life sciences venture capital investor at Aisling Capital LLC. Previously, from 2004 to 2006, Dr. Bilenker served as a Medical Officer at the US FDA, in the Office of Oncology. Dr. Bilenker trained at the University of Pennsylvania in internal medicine and medical oncology, earning board certification in these specialties. He received his M.D. from The Johns Hopkins School of Medicine and his A.B. degree in English from Princeton University.
Founder and Chief Executive Officer, Loxo Oncology
Interim Senior Vice President of Oncology Research and Early Phase Development, Eli Lilly and Company